348 related articles for article (PubMed ID: 25535367)
1. A peripheral endocannabinoid mechanism contributes to glucocorticoid-mediated metabolic syndrome.
Bowles NP; Karatsoreos IN; Li X; Vemuri VK; Wood JA; Li Z; Tamashiro KL; Schwartz GJ; Makriyannis AM; Kunos G; Hillard CJ; McEwen BS; Hill MN
Proc Natl Acad Sci U S A; 2015 Jan; 112(1):285-90. PubMed ID: 25535367
[TBL] [Abstract][Full Text] [Related]
2. Peripheral endocannabinoid signaling controls hyperphagia in western diet-induced obesity.
Argueta DA; DiPatrizio NV
Physiol Behav; 2017 Mar; 171():32-39. PubMed ID: 28065722
[TBL] [Abstract][Full Text] [Related]
3. CB1 receptor mediates the effects of glucocorticoids on AMPK activity in the hypothalamus.
Scerif M; Füzesi T; Thomas JD; Kola B; Grossman AB; Fekete C; Korbonits M
J Endocrinol; 2013 Oct; 219(1):79-88. PubMed ID: 23884964
[TBL] [Abstract][Full Text] [Related]
4. Novel effects of the cannabinoid inverse agonist AM 251 on parameters related to metabolic syndrome in obese Zucker rats.
Merroun I; Sánchez-González C; Martínez R; López-Chaves C; Porres JM; Aranda P; Llopis J; Galisteo M; Zarzuelo A; Errami M; López-Jurado M
Metabolism; 2013 Nov; 62(11):1641-50. PubMed ID: 23932644
[TBL] [Abstract][Full Text] [Related]
5. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice.
Osei-Hyiaman D; Liu J; Zhou L; Godlewski G; Harvey-White J; Jeong WI; Bátkai S; Marsicano G; Lutz B; Buettner C; Kunos G
J Clin Invest; 2008 Sep; 118(9):3160-9. PubMed ID: 18677409
[TBL] [Abstract][Full Text] [Related]
6. Understanding metabolic homeostasis and imbalance: what is the role of the endocannabinoid system?
Kunos G
Am J Med; 2007 Sep; 120(9 Suppl 1):S18-24; discussion S24. PubMed ID: 17720356
[TBL] [Abstract][Full Text] [Related]
7. Participation of endocannabinoids in rapid suppression of stress responses by glucocorticoids in neonates.
Buwembo A; Long H; Walker CD
Neuroscience; 2013 Sep; 249():154-61. PubMed ID: 23131711
[TBL] [Abstract][Full Text] [Related]
8. Targeting the endocannabinoid/CB1 receptor system for treating obesity in Prader-Willi syndrome.
Knani I; Earley BJ; Udi S; Nemirovski A; Hadar R; Gammal A; Cinar R; Hirsch HJ; Pollak Y; Gross I; Eldar-Geva T; Reyes-Capo DP; Han JC; Haqq AM; Gross-Tsur V; Wevrick R; Tam J
Mol Metab; 2016 Dec; 5(12):1187-1199. PubMed ID: 27900261
[TBL] [Abstract][Full Text] [Related]
9. Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome.
Vemuri VK; Janero DR; Makriyannis A
Physiol Behav; 2008 Mar; 93(4-5):671-86. PubMed ID: 18155257
[TBL] [Abstract][Full Text] [Related]
10. New insights on the role of the endocannabinoid system in the regulation of energy balance.
Gatta-Cherifi B; Cota D
Int J Obes (Lond); 2016 Feb; 40(2):210-9. PubMed ID: 26374449
[TBL] [Abstract][Full Text] [Related]
11. Acute overactive endocannabinoid signaling induces glucose intolerance, hepatic steatosis, and novel cannabinoid receptor 1 responsive genes.
Ruby MA; Nomura DK; Hudak CS; Barber A; Casida JE; Krauss RM
PLoS One; 2011; 6(11):e26415. PubMed ID: 22073164
[TBL] [Abstract][Full Text] [Related]
12. Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders.
Silvestri C; Di Marzo V
Expert Opin Investig Drugs; 2012 Sep; 21(9):1309-22. PubMed ID: 22780328
[TBL] [Abstract][Full Text] [Related]
13. 11-Dehydrocorticosterone causes metabolic syndrome, which is prevented when 11β-HSD1 is knocked out in livers of male mice.
Harno E; Cottrell EC; Keevil BG; DeSchoolmeester J; Bohlooly-Y M; Andersén H; Turnbull AV; Leighton B; White A
Endocrinology; 2013 Oct; 154(10):3599-609. PubMed ID: 23832962
[TBL] [Abstract][Full Text] [Related]
14. Glucocorticoid interactions with the dorsal striatal endocannabinoid system in regulating inhibitory avoidance memory.
Siller-Pérez C; Fuentes-Ibañez A; Sotelo-Barrera EL; Serafín N; Prado-Alcalá RA; Campolongo P; Roozendaal B; Quirarte GL
Psychoneuroendocrinology; 2019 Jan; 99():97-103. PubMed ID: 30216767
[TBL] [Abstract][Full Text] [Related]
15. Anandamide drives cell cycle progression through CB1 receptors in a rat model of synchronized liver regeneration.
Pisanti S; Picardi P; Pallottini V; Martini C; Petrosino S; Proto MC; Vitale M; Laezza C; Gazzerro P; Di Marzo V; Bifulco M
J Cell Physiol; 2015 Dec; 230(12):2905-14. PubMed ID: 25684344
[TBL] [Abstract][Full Text] [Related]
16. Antagonism of peripheral hepatic cannabinoid receptor-1 improves liver lipid metabolism in mice: evidence from cultured explants.
Jourdan T; Demizieux L; Gresti J; Djaouti L; Gaba L; Vergès B; Degrace P
Hepatology; 2012 Mar; 55(3):790-9. PubMed ID: 21987372
[TBL] [Abstract][Full Text] [Related]
17. The role of the endocannabinoid system in the control of energy homeostasis.
Osei-Hyiaman D; Harvey-White J; Bátkai S; Kunos G
Int J Obes (Lond); 2006 Apr; 30 Suppl 1():S33-8. PubMed ID: 16570103
[TBL] [Abstract][Full Text] [Related]
18. Prolonged glucocorticoid treatment decreases cannabinoid CB1 receptor density in the hippocampus.
Hill MN; Carrier EJ; Ho WS; Shi L; Patel S; Gorzalka BB; Hillard CJ
Hippocampus; 2008; 18(2):221-6. PubMed ID: 18058925
[TBL] [Abstract][Full Text] [Related]
19. [The endocannabinoid system role in the pathogenesis of obesity and depression].
Zdanowicz A; Kaźmierczak W; Wierzbiński P
Pol Merkur Lekarski; 2015 Jul; 39(229):61-6. PubMed ID: 26277182
[TBL] [Abstract][Full Text] [Related]
20. The endocannabinoid system: a new target for the regulation of energy balance and metabolism.
Després JP
Crit Pathw Cardiol; 2007 Jun; 6(2):46-50. PubMed ID: 17667864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
